Catalent, Inc. Appoints Thomas Castellano as Vice President Finance, Investor Relations, and Treasurer

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has appointed Thomas Castellano as Vice President Finance, Investor Relations, and Treasurer effective immediately.

"We are very pleased that Tom will now lead our investor relations efforts"
Mr. Castellano joined Catalent in 2008 when the Company formed its Financial Planning and Analysis (FP&A) group and was actively involved in building out its financial operations. His role at Catalent expanded in December 2014, when he was named Treasurer of the Company.

"We are very pleased that Tom will now lead our investor relations efforts," said John Chiminski, President and Chief Executive Officer of Catalent, Inc. "During his years with Catalent, he has played a critical role in the Company's transformational journey and in our July 2014 initial public offering. His expertise in financial leadership and capital markets, as well as his profound knowledge of Catalent's operations, will be invaluable in building relationships with Wall Street and our shareholders."

Prior to joining Catalent, Mr. Castellano worked with the Capital Markets Finance group at Lehman Brothers, where he held roles of increasing responsibility. He began his career at Cendant Corporation as part of its Financial Leadership Development Program and was later promoted into the FP&A group of its Real Estate Division. While at Cendant, he participated in the successful spin-off of Realogy Holdings Corporation in 2006.

"Catalent has a very compelling and diverse portfolio of technologies and products. I look forward to communicating our story to investors and analysts as we continue to execute on our business strategy and expand our market share," commented Mr. Castellano.

Mr. Castellano holds a BS in Finance and an MBA with an emphasis in Finance, both from Seton Hall University.

In addition to leading the Investor Relations function, Mr. Castellano will continue to oversee Catalent's FP&A group and remain Treasurer of the Company.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, please visit

Forward-Looking Statements

This release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "project," "foresee," "likely," "may," "will," "would" or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent, Inc.'s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: participation in a highly competitive market and increased competition may adversely affect the business of the Company; demand for the Company's offerings which depends in part on the Company's customers' research and development and the clinical and market success of their products; product and other liability risks that could adversely affect the Company's results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on our business and subject the Company to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to the operations of the Company; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products the Company manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar and other foreign currencies; adverse tax legislation initiatives or challenges to the Company's tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisitions and other transactions that may complement or expand the business of the Company or divest of non-strategic businesses or assets and the Company's ability to successfully integrate acquired business and realize anticipated benefits of such acquisitions; offerings and customers' products that may infringe on the intellectual property rights of third parties; environmental, health and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations; additional cash contributions required to fund the Company's existing pension plans; substantial leverage resulting in the limited ability of the Company to raise additional capital to fund operations and react to changes in the economy or in the industry, exposure to interest rate risk to the extent of the Company's variable rate debt and preventing the Company from meeting our obligations under our indebtedness. For a more detailed discussion of these and other factors, see the information under the caption "Risk Factors" in our 10-K for the fiscal year ended June 30, 2014, filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent, Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.

More products. Better treatments. Reliably supplied.™


Catalent, Inc.
Thomas Castellano, 732-537-6325
[email protected]
Bertner Advisors
Jeremy Feffer, 732-537-6325
[email protected]

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.